Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Bio Medica Laboratories's Enterprise Value is ₹2,192.4 Mil.
Bio Medica Laboratories does not have enough years/quarters to calculate its EBIT for the trailing twelve months (TTM) ended in Mar. 2025. Therefore, GuruFocus does not calculate Bio Medica Laboratories's EV-to-EBIT at this moment.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Bio Medica Laboratories's Enterprise Value is ₹2,192.4 Mil.
Bio Medica Laboratories does not have enough years/quarters to calculate its EBITDA for the trailing twelve months (TTM) ended in Mar. 2025. Therefore, GuruFocus does not calculate Bio Medica Laboratories's EV-to-EBITDA at this moment.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Bio Medica Laboratories's Enterprise Value is ₹2,192.4 Mil.
Bio Medica Laboratories does not have enough years/quarters to calculate its Revenue for the trailing twelve months (TTM) ended in Mar. 2025. Therefore, GuruFocus does not calculate Bio Medica Laboratories's EV-to-Revenue at this moment.
EV-to-FCF is calculated as Enterprise Value divided by its Free Cash Flow. As of today, Bio Medica Laboratories's Enterprise Value is ₹2,192.4 Mil.
Bio Medica Laboratories does not have enough years/quarters to calculate its Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2025. Therefore, GuruFocus does not calculate Bio Medica Laboratories's EV-to-FCF at this moment.
*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.
Bio Medica Laboratories (NSE:BMLL) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
Bio Medica Laboratories Enterprise Value Related Terms
Bio Medica Laboratories Enterprise Value Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bio Medica Laboratories Enterprise Value Chart
Bio Medica Laboratories Annual Data
Trend
Mar23
Mar24
Mar25
Enterprise Value
0.00
0.00
0.00
Bio Medica Laboratories Semi-Annual Data
Mar23
Mar24
Mar25
Enterprise Value
0.00
0.00
0.00
NSE:BMLL vs ISRG, BDX, MDLN: Enterprise Value Comparison
For the Medical Instruments & Supplies subindustry, Bio Medica Laboratories's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bio Medica Laboratories Enterprise Value vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Bio Medica Laboratories's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Bio Medica Laboratories's Enterprise Value falls into.
Bio Medica Laboratories Enterprise Value Calculation
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Bio Medica Laboratories's Enterprise Value for the fiscal year that ended in Mar. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Enterprise Value of ₹2,192.4 Mil mean?
Bio Medica Laboratories (NSE:BMLL) has a Enterprise Value of ₹2,192.4 Mil as of Jun. 29, 2026. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Bio Medica Laboratories and its competitors.
Is Bio Medica Laboratories' Enterprise Value too high?
Bio Medica Laboratories' current Enterprise Value is ₹2,192.4 Mil. Overall, Bio Medica Laboratories has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Bio Medica Laboratories' Enterprise Value compare to ISRG and BDX?
Bio Medica Laboratories' Enterprise Value of ₹2,192.4 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Enterprise Value for a Medical Devices & Instruments company?
A good Enterprise Value depends on the Medical Devices & Instruments industry context. However, Enterprise Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Enterprise Value mean?
A high Enterprise Value can signal that a stock is expensive relative to its fundamentals. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Bio Medica Laboratories and its competitors. Bio Medica Laboratories's current Enterprise Value is ₹2,192.4 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bio Medica Laboratories stock overvalued right now?
Bio Medica Laboratories (NSE:BMLL) has a current Enterprise Value of ₹2,192.4 Mil. The current Enterprise Value is ₹2,192.4 Mil. Bio Medica Laboratories' overall GF Score™ is 14/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Enterprise Value calculated?
Enterprise Value is calculated from a company's financial statements. For Bio Medica Laboratories (NSE:BMLL), the current Enterprise Value is ₹2,192.4 Mil as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Bio Medica Laboratories Ltd is engaged in the manufacturing of Pharmaceutical Parenteral Formulations. It manufactures generic drugs in the form of injectables namely Liquid Injections and Dry Powder Injections. These injectables are available in both single dose and multi dose forms, catering both human and veterinary needs. Its products address a wide range of medical needs and preferences. The majority of revenue is derived from the sales of Liquid injections. Geographically, it operates predominantly in India, and internationally, it exports to Afghanistan.
14GF Score
Get the complete analysis for NSE:BMLL
Enterprise Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:BMLL has been successfully added to your 